IPSEN (OTCMKTS:IPSEY) Sees Large Increase in Short Interest

IPSEN (OTCMKTS:IPSEY) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 268 shares, a growth of 87.4% from the June 15th total of 143 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 1,589 shares, the days-to-cover ratio is presently 0.2 days.

IPSEN Price Performance

OTCMKTS:IPSEY opened at $44.07 on Friday. IPSEN has a 52-week low of $30.05 and a 52-week high of $51.10. The stock has a fifty day moving average of $46.54 and a 200 day moving average of $44.81.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold”.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).